Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 10 , Pages 1011-1023, October 2010

Methylphenidate and Atomoxetine Enhance Prefrontal Function Through α2-Adrenergic and Dopamine D1 Receptors

  • Nao J. Gamo, M.Phil.
    • ,
  • Min Wang, Ph.D.
    • ,
  • Amy F.T. Arnsten, Ph.D.

      Affiliations

    • Corresponding Author InformationCorrespondence to Amy F.T. Arnsten, Ph.D., Department of Neurobiology, Yale Medical School, 333 Cedar St., New Haven, CT 06510

Accepted 29 June 2010. published online 02 September 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This article is discussed in an editorial by Dr. F. Xavier Castellanos on page 977.

 This article was reviewed under and accepted by Associate Editor James J. Hudziak, M.D.

 This research was supported by a grant from Shire Pharmaceuticals to Dr. Arnsten as part of an overarching goal to further understanding of the neurobiological bases of ADHD and its treatment.

 Disclosure: Dr. Arnsten and Yale University have a license agreement and receive royalties from Shire Pharmaceuticals for the development of guanfacine (Intuniv™) for the treatment of ADHD and related disorders. Dr. Arnsten also performs consulting, teaching, and speaking engagements for Shire Pharmaceuticals. Dr. Arnsten has provided consultation to Eli Lilly and Co. in the past but not in regard to the present research. Dr. Gamo previously owned stock in Shire Pharmaceuticals but has since divested. Dr. Wang reports no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(10)00522-8

doi:10.1016/j.jaac.2010.06.015

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 10 , Pages 1011-1023, October 2010

Article Tools

* Image Usage & Resolution